echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hengrui Medicine Fondaparinux Sodium Injection Passed Consistency Evaluation

    Hengrui Medicine Fondaparinux Sodium Injection Passed Consistency Evaluation

    • Last Update: 2021-07-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On July 28, Hengrui Medicine issued an announcement stating that it had recently received the "Drug Supplementary Application Approval Notice" for Fondaparinux Sodium Injection approved and issued by the State Food and Drug Administration, and the drug passed the consistency evaluation of generic drugs


    The drug indications:

    1.


    2.


    3.


    Fondaparinux is a synthetic, selective inhibitor of activated factor X.


    Fondaparinux was jointly developed by Organon and Sanofi.


    Data show that the global sales of Fondaparinux sodium injection in 2020 will be approximately US$191 million


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.